rt-PA与尿激酶在急性心肌梗死溶栓治疗的疗效对比

Comparison of Efficacy of rt-PA and Urokinase in Thrombolytic Therapy of Acute Myocardial Infarction

目的对比重组组织型纤溶酶原激活剂(rt-PA)与尿激酶在急性心肌梗死溶栓治疗的疗效。方法将我院于2013年1月—2015年1月收治的73例急性心肌梗死患者随机分为观察组和对照组,对照组采用尿激酶溶栓治疗,观察组采用rt-PA溶栓治,对比两组的疗效。结果观察组再通率为86.4%(32/37),高于对照组的61.1%(22/36),组间对比,差异具有统计学意义(P<0.05)。两组患者住院30 d病死率和不良反应发生率对比,差异不具有统计学意义(P>0.05)。结论应用rt-PA进行急性心肌梗死溶栓治疗安全性和有效性良好。

Objective To compare the recombinant tissue plasminogen activator（rt-PA） treatment with urokinase in acute myocardial infarction. Methods In our hospital from January 2013 to January 2015, 73 cases of patients with acute myocardial infarction were randomly divided into observation group and control group, the control group using urokinase thrombolysis treatment, the observation group with rt-PA thrombolytic treatment, efficacy of the two groups were compared. Results The recanalization rate of observation group was 86.4%（32/37）, higher than the control group 61.1%（22/36）, the comparison between the two groups, the difference was statistically significant（P〈0.05） in group. The occurrence of 30 d mortality and adverse reaction rate in comparison, the difference was not statistically significant（P〉0.05）. Conclusion The application of rt-PA thrombolytic therapy of acute myocardial infarction is safe and effective.